- Home
- CYCN vs DRCT Comparison
CYCN vs DRCT Comparison
Compare CYCN & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- DRCT
- Stock Information
- Founded
- CYCN 2018
- DRCT 2018
- Country
- CYCN United States
- DRCT United States
- Employees
- CYCN N/A
- DRCT N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- CYCN Health Care
- DRCT Technology
- Exchange
- CYCN Nasdaq
- DRCT Nasdaq
- Market Cap
- CYCN 8.0M
- DRCT 9.2M
- IPO Year
- CYCN N/A
- DRCT 2022
- Fundamental
- Price
- CYCN $2.43
- DRCT $0.42
- Analyst Decision
- CYCN
- DRCT Strong Buy
- Analyst Count
- CYCN 0
- DRCT 1
- Target Price
- CYCN N/A
- DRCT $6.00
- AVG Volume (30 Days)
- CYCN 25.2K
- DRCT 216.2K
- Earning Date
- CYCN 11-13-2025
- DRCT 11-11-2025
- Dividend Yield
- CYCN N/A
- DRCT N/A
- EPS Growth
- CYCN N/A
- DRCT N/A
- EPS
- CYCN N/A
- DRCT N/A
- Revenue
- CYCN $2,174,000.00
- DRCT $36,459,000.00
- Revenue This Year
- CYCN N/A
- DRCT $16.81
- Revenue Next Year
- CYCN N/A
- DRCT $35.28
- P/E Ratio
- CYCN N/A
- DRCT N/A
- Revenue Growth
- CYCN N/A
- DRCT N/A
- 52 Week Low
- CYCN $1.27
- DRCT $0.38
- 52 Week High
- CYCN $9.47
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- CYCN 47.88
- DRCT 46.86
- Support Level
- CYCN $2.13
- DRCT $0.40
- Resistance Level
- CYCN $2.59
- DRCT $0.49
- Average True Range (ATR)
- CYCN 0.20
- DRCT 0.03
- MACD
- CYCN 0.02
- DRCT 0.00
- Stochastic Oscillator
- CYCN 49.18
- DRCT 43.65
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.